Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
innovation crawled date : 2021 - 06 - 07 save search
OFC 2021 Opens with the Innovations and Solutions Critical to Addressing Ever-increasing Data Demand
Published: 2021-06-07 (Crawled : 15:15) - prnewswire.com
SNPS A | $510.65 -1.74% -1.77% 1.2M
|
Technology Services
|
| O: -0.3%
H: 0.05%
C: -0.99%
AVGO | News S | $1204.26 -4.35% -4.54% 4.5M
|
Electronic Technology
|
| O: -0.42%
H: 0.31%
C: -1.95%
Kimberly-Clark Partners with Biotech Innovator RWDC to Design Sustainable Alternatives to Traditional Plastics
Published: 2021-06-07 (Crawled : 14:15) - prnewswire.com
KMB | $126.83 0.97% 0.0% 4.8M
|
Consumer Non-Durables
|
| O: 0.07%
H: 0.44%
C: 0.32%
biotech iot designation
Teleflex to Present at the Raymond James 2021 Human Health Innovation Conference
Published: 2021-06-07 (Crawled : 11:00) - globenewswire.com
TFX | News | $206.56 -0.4% 0.0% 420K
|
Health Technology
|
| O: 0.13%
H: 0.85%
C: -0.75%
conference health
AnHeart and Innovent Releases Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting
Published: 2021-06-07 (Crawled : 07:00) - biospace.com/
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.01%
H: 15.52%
C: 10.16%
heart positive results trial
Innovent and AnHeart Release Preliminary Results from the Phase II TRUST Trial of Taletrectinib in ROS1 Fusion Positive NSCLC at the ASCO 2021 Annual Meeting
Published: 2021-06-07 (Crawled : 01:00) - prnewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.01%
H: 15.52%
C: 10.16%
heart positive results trial
Innovent Releases Phase 1 Results of Pemigatinib in Chinese Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021
Published: 2021-06-07 (Crawled : 01:00) - prnewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.01%
H: 15.52%
C: 10.16%
INCY | $52.3 -0.98% -0.99% 2.2M
|
Health Technology
|
| O: 0.18%
H: 2.77%
C: 1.95%
chinese solid tumors phase 1 results phase 3 phase 2
Innovent and HUTCHMED Release Phase 1b preliminary Results of TYVYT (Sintilimab Injection) plus Fruquintinib as a Third Line Treatment for Advanced Colorectal Cancer at ASCO Annual Meeting 2021
Published: 2021-06-07 (Crawled : 01:00) - prnewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.01%
H: 15.52%
C: 10.16%
treatment phase 1 injection results cancer colorectal cancer phase 1b phase 2b
Innovent Releases the Phase Ia/Ib Dose-Escalation Trial Results of IBI110 (anti-LAG-3) in Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021
Published: 2021-06-07 (Crawled : 01:00) - prnewswire.com
LLY | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: -0.01%
H: 15.52%
C: 10.16%
solid tumors results trial trial results
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | News | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.